{"id":"pecfent-and-epistatus","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nasal irritation (PecFent)"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL1628401","moleculeType":"Small molecule","molecularWeight":"657.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PecFent (fentanyl pectin nasal spray) is a potent mu-opioid receptor agonist formulated for rapid transmucosal absorption via the nasal cavity, providing fast-acting pain relief. Epistatus (midazolam oromucosal solution) is a benzodiazepine that enhances GABAergic inhibitory neurotransmission in the central nervous system, rapidly terminating acute seizures. Both are designed for rapid onset of action via non-intravenous routes.","oneSentence":"PecFent is a fentanyl nasal spray that delivers rapid opioid analgesia through intranasal absorption, while Epistatus is a midazolam buccal liquid that provides rapid seizure termination through GABA-A receptor agonism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:10.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breakthrough cancer pain in opioid-tolerant patients (PecFent)"},{"name":"Acute seizure termination and cluster seizures (Epistatus)"}]},"trialDetails":[{"nctId":"NCT02009306","phase":"PHASE4","title":"Nasal Fentanyl and Buccal Midazolam for Dying Patients","status":"COMPLETED","sponsor":"Gloucestershire Hospitals NHS Foundation Trust","startDate":"2017-01-23","conditions":"Terminal Cancer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fentanyl and Midazolam"],"phase":"marketed","status":"active","brandName":"PecFent and Epistatus","genericName":"PecFent and Epistatus","companyName":"Gloucestershire Hospitals NHS Foundation Trust","companyId":"gloucestershire-hospitals-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PecFent is a fentanyl nasal spray that delivers rapid opioid analgesia through intranasal absorption, while Epistatus is a midazolam buccal liquid that provides rapid seizure termination through GABA-A receptor agonism. Used for Breakthrough cancer pain in opioid-tolerant patients (PecFent), Acute seizure termination and cluster seizures (Epistatus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}